Physician profile
Todd E Perkins
NPI 1982641148
$102,281.18
in general payments reported to CMS, 2019-2025
42 companies · $9,808 in 2025
The $9,808 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $9,746 · 2021: $9,641 · 2022: $25K · 2023: $11K · 2024: $11K · 2025: $9,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $8,501 · Consulting Fee: $1,180 · Travel and Lodging: $578 · Education: $34.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,775.00 |
| Food and Beverage | $8,500.85 |
| Consulting Fee | $1,180.00 |
| Travel and Lodging | $577.80 |
| Education | $34.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $83,060.71 | 2019-2025 | |
| Pfizer INC. | $6,904.25 | 2019-2025 | |
| Ucb, INC. | $1,754.31 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $1,076.12 | 2021-2025 | |
| Lilly USA, LLC | $995.55 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $958.98 | 2019-2025 | Adbry, Spevigo, Anzupgo |
| Sun Pharmaceutical Industries INC. | $919.10 | 2019-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $895.97 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Regeneron Healthcare Solutions, INC. | $642.25 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $616.78 | 2019-2025 | |
| Incyte Corporation | $593.01 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $553.63 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Arcutis Biotherapeutics, INC. | $510.69 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $365.75 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $341.97 | 2019-2024 | Jublia, Arazlo, Duobrii |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.